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Objectives. The aim of our study was to analyse, in
a wide group of essential hypertensive patients
without diabetes mellitus, the influence of
metabolic syndrome (MS) (defined according to the
criteria laid down in the Third Report of the
National Cholesterol Education Program Expert
Panel on Detection, Evaluation, and Treatment of
High Blood Cholesterol in Adults) on markers of
preclinical cardiac, renal and retinal damage.
Design. Cross-sectional study.
Setting. Outpatient hypertension clinic.
Subjects and methods. A total of 353 young and
middle-aged hypertensives, free from cardiovascular
and renal diseases (and 37% of whom had
MS), underwent echocardiographic examination,
microalbuminuria determination and non-mydriatic
retinography.
Results. When compared with subjects without
MS, hypertensive patients with MS exhibited
more elevated left ventricular (LV) mass (either
normalized by body surface area or by height
elevated by a power of 2.7), higher myocardial
relative wall thickness, albumin excretion rate
(AER) and a greater prevalence of LV hypertrophy
(57.7% vs. 25.1%; P < 0.00001), of micro-
albuminuria (36.2% vs. 19.3%; P ¼ 0.002) and of
hypertensive retinopathy (87.7% vs. 48.4%;
P < 0.00001). These results held even after
correction for age, 24-h blood pressures, duration
of hypertension, previous antihypertensive therapy,
and gender distribution. The independent
relationships between LV mass and MS, and
between AER and MS, were confirmed in
multivariate regression models including MS
together with its individual components.
Conclusions. MS may amplify hypertension-related
cardiac and renal changes, over and above the
potential contribution of each single component of
this syndrome. As these markers of target organ
damage are well-known predictors of
cardiovascular events, our results may partly
explain the enhanced cardiovascular risk
associated with MS.
Keywords: essential hypertension, left ventricular
hypertrophy, metabolic syndrome, microalbuminuria,
target organ damage.
Introduction
Arterial hypertension is often associated with var-
ious metabolic abnormalities including abdominal
obesity, dyslipidaemia, elevated plasma glucose and
insulin resistance, which are the main features of
the metabolic syndrome (MS), previously known
as either the insulin resistance syndrome, or X
syndrome or deadly quartet [1], or dysmetabolic
syndrome [2]. Recently, the World Health Organ-
ization (WHO) [1], the American Association of
Clinical Endocrinologists [1] and the Third Report of
the National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, and Treat-
ment of High Blood Cholesterol in Adults (ATPIII)
[3] proposed working definitions for this syndrome.
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Amongst these definitions the one suggested by
NCEP-ATPIII is the simplest and the most practical
and according to which MS may be diagnosed when
three or more abnormalities (impaired glucose
metabolism, elevated blood pressure, hypertriglyce-
ridaemia, low HDL cholesterol and central obesity)
cluster in the same person [3]. The adverse prog-
nostic impact of the MS, as defined by NCEP-ATPIII,
has recently been documented in men [4] and in
women [5] with no history of cardiovascular
disease, in hypercholesterolaemic men [6] and in
hypertensive patients [7]. It is conceivable that the
increased cardiovascular risk conferred by MS in
hypertensive subjects may in part be mediated
through preclinical end-organ damage.
Our study was undertaken to evaluate the influ-
ence of MS, defined according to the NCEP-ATPIII
criteria, on some cardiac, renal and retinal markers
of target organ damage, in a large group of non-
diabetic young and middle-aged essential hyperten-
sives without clinical or laboratory evidence of
cardiovascular and renal diseases.
Methods
The study population was selected from 478 hyper-
tensive patients consecutively attending our hyper-
tension centre. Most of them had been referred to
our institution by their general practitioners for
specialist advice. Eighty subjects were not enrolled
because of secondary or malignant hypertension,
heart failure, positive history or clinical signs of
ischaemic heart disease, cerebrovascular disease,
renal insufficiency (serum creatinine >133
lmol L)1 (1.5 mg dL)1) in men and >124 lmol L)1
(1.4 mg dL)1) in women), overt proteinuria, major
non-cardiovascular diseases, dyslipidaemia requi-
ring pharmacological treatment, and known diabe-
tes or fasting glycaemia ‡126 mg dL)1.
Of the remaining hypertensive individuals 45
were also excluded, because of suboptimal echocar-
diographic tracings (39 subjects) or unreliable urine
collections (six patients). Hence, the final statistical
analysis involved 353 patients. Before entering the
study, 230 hypertensives had been pharmacologi-
cally treated. These patients were studied for at least
2 weeks, after the discontinuation of all antihyper-
tensive drugs. Written informed consent was
obtained from each patient and the study was
approved by the local ethics committee.
Study design
In all subjects careful clinical history and physical
examination were performed. After the period of
pharmacological washout, body weight, height, and
waist circumference were measured by a nurse and
clinical blood pressure was recorded by a doctor. The
latter was considered as the average of three
consecutive measurements obtained by a mercury
sphygmomanometer, after the subject had been
supine for 5 min.
Additionally, urine analysis was performed and a
24-h urine sample was collected to evaluate the
levels of albumin excretion rate (AER) and creati-
nine clearance. The following morning, after an
overnight fast of at least 10 h, blood samples were
drawn to perform routine blood chemistry. The 24-h
urine collection was repeated within 1 week to
assay AER again. Both urine collections were carried
out on two non-working days, during which the
patients were advised to avoid excessive physical
effort. Furthermore, 24-h ambulatory blood pressure
monitoring (ABPM), echocardiographic study and
fundal examinations were carried out.
Measurements
Determination of routine biochemical parameters
was performed with standard techniques by using
an autoanalyser (Boehringer Mannheim for Hitachi
system 911, Mannheim, Germany). Low-density
lipoprotein cholesterol (LDL) was calculated by the
Friedwald formula. Microalbuminuria was analysed
by radioimmunological assay (Techno Genetics RIA
Kit, Techno Genetics, Milan, Italy). The sensitivity of
this method is 0.5 lg mL)1, the transferrine cross
reactivity is <0.01% and the intra-assay and inter-
assay coefficient of variation were £5.1% and £7.2%
respectively.
The average of two AER determinations was
considered as the level of albuminuria in each
subject. The currently considered threshold for the
definition of microalbuminuria was used to separate
microalbuminuric (AER ‡ 20 lg min)1) from
normoalbuminuric subjects (AER < 20 lg min)1).
As detailed in the NCEP-ATPIII report [3], the MS
was defined by the presence, in addition to hyper-
tension, of two or more of the following criteria:
high-density lipoprotein (HDL) <1.04 mmol L)1
(40 mg dL)1) in men or <1.29 mmol L)1
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(50 mg dL)1) in women; fasting glucose between
6.1 and 6.94 mmol L)1 (110–125 mg dL)1); tri-
glycerides >1.69 mmol L)1 (150 mg dL)1); and
waist circumference >102 cm in men or >88 cm
in women [2].
A portable, non-invasive SpaceLabs 90207 recor-
der (Redmond, WA, USA) was used to perform the
24-h ABPM. M-mode echocardiography, guided by a
two-dimensional echocardiography, was performed
with the patient maintained in a partial left decub-
itus position, using an Acuson Sequoia 512 (Sie-
mens, Mountain View, CA, USA)
M-mode measurements were taken at end diastole
and end systole in line with the American Society of
Echocardiography (ASE) recommendations [8]. Only
those frames with optimal visualization of interfaces
and showing simultaneous visualization of septum,
left ventricular (LV) internal diameter and posterior
wall were used for readings. Myocardial relative wall
thickness was calculated as twice posterior wall in
diastole divided by internal diameter, and was used
as an estimate of LV geometry.
Left ventricular mass was determined using the
ASE-corrected cube formula [9]: 0.80 · {1.04 ·
[(septal thickness + LV internal diameter + poster-
ior wall thickness)3 ) (LV internal diam-
eter)3]} + 0.6 g. It was indexed by both body
surface area (LVMI) and by height elevated by a
power of 2.7, as suggested by de Simone et al. [10],
in order to provide a more stringent allowance for
obesity (LVMH2.7).
Left ventricular hypertrophy was defined as
LVMI ‡ 125 g m)2 for men and ‡110 g m)2 for
women, as suggested by the 2003 guidelines
of the European Society of Hypertension [11]
and as LVMH2.7 ‡ 49.2 g m)2.7 for men and
‡46.7 g m)2.7 for women, which represent the
upper limits of normal sex-specific 95% confidence
intervals (95% CIs) in reference populations [12].
Left ventricular shortening at the endocardium
and mid-wall were used as estimates of LV
chamber and myocardial systolic function. Frac-
tional shortening at the endocardium was calcu-
lated as the difference between the end-diastolic
and end-systolic internal diameter divided by the
end-diastolic diameter and then multiplied by 100.
Myocardial function was assessed as mid-wall
circumferential shortening and calculated using a
two-shell cylindrical model, as previously described
[13].
The pulsed-Doppler examination of transmitral
blood flow was performed from the apical four-
chamber view by using a 2.5-MHz transducer, with
the sample at the level of the tip of mitral valve
leaflets. The parameters measured from the Doppler
waveform were: the early filling peak velocity (E
wave), the late filling peak velocity (A wave) and
their ratio (E/A ratio). Moreover, the time of E
velocity deceleration was measured as the interval
between the peak E velocity and the point at which
the descending segment of the E-wave, or its
asymptote, crosses the zero-velocity line.
Echocardiographic data is expressed as the aver-
age of five consecutive cardiac cycles. Images were
read blindly by a single cardiologist, unaware of the
patient’s clinical characteristics. In our laboratory,
the mean intra-observer variability was 8.6% for LV
mass and 7.8% and 8.9%, respectively, for peak
velocities in early and late filling. The ocular fundus
examination was carried out by means of a bilateral
non-mydriatic retinography (Canon CR4–45 NM,
Tokio, Japan). A single examiner, unaware of the
patient’s clinical data, assessed the presence and the
grading of hypertensive retinopathy, using this
simplified Keith, Wagener and Barker classification
[14]: grade I was taken as an arteriolar diameter
£50% of the venous diameter; grade II as arterio-
venous crossing changes (nicking) situated at more
than one papillary diameter from the papilla; grade
III as the presence of retinal haemorrhages or
exudates; grade IV as the presence of papillary
oedema and retinal haemorrhages and/or exudates.
Statistics
Continuous variables were given as mean ± SD,
except for AER, which, because of its skewed distri-
bution, was expressed as the median and interquar-
tile range. It was subsequently log-transformed before
starting the statistical tests. Differences between
groups with and without MS were evaluated using
the independent-sample Student’s t-test for continu-
ous variables and the chi-square test, with Yates’
correction, for the categorical variables. Adjustment
for age, gender and other potential confounders was
carried out, where appropriate, by analysis of cova-
riance and multiple logistic regression analysis.
Stepwise multiple linear regression analyses were
used to test independent correlates of LV mass and
AER. Initially, age, gender, duration of hyperten-
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sion, 24-h blood pressures, previous antihyperten-
sive therapy and each individual component of MS
(the latter either as continuous or as dichotomous
variables) were considered in order to build the
multiple regression models. Subsequently we ran the
models again, after adding MS as a dummy variable.
Because of the high degree of collinearity between
MS and its individual components, ordinary least-
squares multiple regression analysis may lead to
inaccurate estimates of the regression coefficients
[15]. For this reason we also use an additional
method of multiple regression, the ridge regression,
which is one of the techniques proposed to overcome
the problem of multicollinearity. A ridge estimator of
regression coefficients is obtained by modifying the
method of least squares (this is made by introducing
a constant ‘lambda’ in the normal equations) to
allow shrunken and biased estimators of regression
coefficients [15]. All tests were considered to be
significant at the level of 2p £ 0.05. The statistical
analyses were performed using the systat data
software package, version 11 (Systat, Richmond,
CA, USA).
Results
Table 1 gives clinical and demographic characteris-
tics of all the subjects included in the study and of
the subgroups into which the study population was
divided in line with the NCEP-ATPIII definition of
MS.
The prevalence of MS in our hypertensive popu-
lation was 37% (130/353). As expected the values
of all anthropometric and metabolic parameters
used for the definition of MS were significantly
higher, and HDL cholesterol level was lower in
hypertensive subjects with MS, when compared with
those without it. Furthermore, patients with MS
were older, had a longer duration of hypertension
and showed higher clinical and 24-h systolic blood
pressures (BP). In the group with MS it was observed
that there was a higher percentage of patients
previously treated pharmacologically for hyperten-
sion and a greater proportion of women. The over-
representation of females in the MS group was
chiefly explained by a greater prevalence of visceral
obesity (59% vs. 27%; P < 0.0001) and of lower
HDL values (62% vs. 28%; P < 0.0001) in females
than in males. The two groups did not differ in terms
of smoking habits, total and LDL cholesterol levels.
Echocardiographic parameters of the study popu-
lation are reported in Table 2. Participants with MS
exhibited significantly higher LV chamber diameter,
posterior wall and interventricular septum thick-
nesses, relative wall thickness, left atrial size, LV
mass, either normalized for body surface area (BSA)
or for height2.7, even after controlling for age,
gender, 24-h blood pressures and duration of
Table 1 Demographic and clinical data of the overall study population and of the two subgroups with and without metabolic syndrome
(MS)
Overall study
population (n ¼ 353)
Patients with
MS (n ¼ 130)
Patients without
MS (n ¼ 223) P
P adjusted for
age and gender
Age (years) 45.9 ± 10.1 48.5 ± 8.5 44.4 ± 10.6 0.0002 –
Gender (male/female) 202 (57)/151 (43) 62 (48)/68 (52) 140 (63)/83 (37) 0.008 –
Current smokers 97 (27) 39 (30) 58 (26) 0.492 –
Body mass index (kg m)2) 27.9 ± 4 30.4 ± 3.5 26.4 ± 3.4 <0.00001 <0.00001
Waist circumference (cm) 95.2 ± 10.9 101.6 ± 9.4 91.5 ± 10 <0.00001 <0.00001
Glycaemia (mmol L)1) 5.17 ± 0.64 5.46 ± 0.73 5.02 ± 0.52 <0.00001 <0.00001
Total cholesterol (mmol L)1) 5.39 ± 1.02 5.54 ± 1.10 5.31 ± 0.97 0.038 0.22
Triglycerides (mmol L)1) 1.15 ± 0.76 1.91 ± 0.88 1.23 ± 0.55 <0.00001 <0.00001
HDL cholesterol (mmol L)1) 1.18 ± 0.26 1.05 ± 0.22 1.26 ± 0.25 <0.00001 <0.00001
LDL cholesterol (mmol L)1) 3.54 ± 0.99 3.63 ± 1.05 3.49 ± 0.95 0.20 0.69
Known hypertension duration (months) 57.1 ± 65.4 66.5 ± 73 53.6 ± 60 0.04 0.21
Previous antihypertensive treatment 230 (65) 97 (74.6) 133 (59.6) 0.006 –
Clinical systolic blood pressure (mmHg) 156.9 ± 18.5 162.6 ± 18.4 153.6 ± 17.8 <0.00001 0.0006
Clinical diastolic blood pressure (mmHg) 95.2 ± 10.8 94.6 ± 10.8 96.2 ± 10.8 0.21 0.22
24-h systolic blood pressure (mmHg) 134.3 ± 12.1 136.8 ± 13.8 132.8 ± 10.8 0.004 0.016
24-h diastolic blood pressure (mmHg) 85.2 ± 9 85.1 ± 8.9 85.3 ± 9.1 0.79 0.87
24-h heart rate (b min)1) 75 ± 8.6 75.7 ± 8.7 74.6 ± 8.4 0.25 0.19
Values are presented as mean ± SD or n (%).
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hypertension. Prevalence of LV hypertrophy was
greater in MS group, either using LVMI (31.5% vs.
13.5%; P ¼ 0.0008) or LVMH2.7 (Fig. 1a). The
increased risk of having LV hypertrophy, in subjects
with MS, remained significant, also taking into
account age, gender, 24-h systolic and diastolic BP,
duration of hypertension, previous antihypertensive
therapy and AER by multiple logistic regression
analyses (odds ratio, OR ¼ 2.20, 95% CI: 1.20–
4.05; P ¼ 0.01, when LV mass was indexed for BSA
and OR ¼ 2.89, 95% CI: 1.68–4.98; P ¼ 0.0001,
when LV mass was indexed for height2.7). Moreover,
analysis of covariance documented that LV mass,
regardless of the method of indexation, was higher
in subjects with MS, also after adjustment for age,
sex, duration of hypertension, previous antihyper-
tensive therapy, 24-h systolic and diastolic blood
pressures and each individual component of MS
(glycaemia, HDL, triglycerides and waist circumfer-
ence) (P ¼ 0.009 for LVMI and P ¼ 0.004 for
LVMH2.7).
Similar results were obtained in the subset (n ¼
123) of hypertensive subjects never pharmacologi-
cally treated for hypertension, amongst whom those
Table 2 Cardiac parameters of the overall study population and of the two subgroups with and without metabolic syndrome (MS)
Overall study
population (n ¼ 353)
Patients with
MS (n ¼ 130)
Patients without
MS (n ¼ 223) P P adjusted*
End-diastolic left ventricular internal dimension (mm) 49.3 ± 5 50 ± 5 48.9 ± 4.9 0.035 0.008
End-diastolic interventricular septum thickness (mm) 10.4 ± 1.7 10.9 ± 1.7 10 ± 1.6 <0.00001 0.00005
End-diastolic posterior wall thickness (mm) 9.8 ± 1.6 10.4 ± 1.7 9.4 ± 1.4 <0.00001 <0.00001
Myocardial relative wall thickness (ratio) 0.41 ± 0.08 0.43 ± 0.08 0.39 ± 0.07 0.0002 0.01
Left ventricular mass indexed for BSA (g m)2) 98.3 ± 24.6 106.9 ± 27 93.4 ± 21.5 <0.00001 0.0007
Left ventricular mass indexed for height2.7 (g m)2.7) 46.3 ± 13 53.1 ± 14.4 42.3 ± 10.3 <0.00001 <0.00001
Left atrial dimension (mm) 34.7 ± 4.6 36.4 ± 4.6 33.9 ± 4.4 <0.00001 0.0005
Endocardial fractional shortening (%) 37.9 ± 5.8 37.5 ± 7 38.5 ± 5 0.12 0.59
Mid-wall fractional shortening (%) 17.2 ± 1.6 16.8 ± 1.7 17.5 ± 1.6 0.0002 0.01
Mitral E-wave/A-wave ratio 1.3 ± 0.41 1.14 ± 0.39 1.35 ± 0.4 <0.00001 0.08
E-wave deceleration time (ms) 208.5 ± 41.2 226.8 ± 50.1 201.8 ± 30.8 <0.00001 0.01
Values are presented as mean ± SD. BSA, body surface area.
*Adjustment was made for age, gender, 24-h systolic and diastolic BP and duration of hypertension.
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Fig. 1 (a) Prevalence of left ventricular hypertrophy (defined as a left ventricular mass indexed by height elevated by a power of
2.7 ‡ 49.2 g m)2.7 in men and ‡46.7 g m)2.7 in women) in hypertensive subjects with and in those without metabolic syndrome. After
adjustment for age, gender, 24-h blood pressures and duration of hypertension, P ¼ 0.0001. (b) Prevalence of microalbuminuria (defined
as albumin excretion rate ‡20 lg min)1) in hypertensive subjects with and in those without metabolic syndrome. After adjustment for age,
gender, 24-h blood pressures and duration of hypertension, P ¼ 0.007.
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with MS (n ¼ 37), when compared with patients
without MS (n ¼ 86), tended to be older (43 ± 9.1
vs. 40.1 ± 9.8; P ¼ 0.13), and showed higher 24-h
systolic BP (135.9 ± 11.5 vs. 130 ± 9.4; P ¼
0.003) and more elevated values of LVMI
(100.5 ± 17.6 g m)2 vs. 86 ± 14.3 g m)2; P <
0.0001, which becomes P ¼ 0.002 after adjustment
for age and 24-h systolic BP) and of LVMH2.7
(47.3 ± 7.8 g m)2.7 vs. 38.6 ± 6.7 g m)2.7; P <
0.0001, which becomes P ¼ 0.0001 after adjust-
ment for age and 24-h systolic BP).
To confirm that the differences in LV mass were
not explained by visceral obesity alone we compared
LVMI and LVMH2.7 in two subgroups of the study
population, including obese subjects (waist circum-
ference >102 cm in men and >88 cm in women)
with MS (n ¼ 93) and obese individuals without MS
(n ¼ 43). Waist circumference and BMI did not
differ in the two groups. Still, we found higher
values of LVMI (106.9 ± 28.6 g m)2 vs. 92.1 ±
22.4 g m)2; P ¼ 0.001) and of LVMH2.7 (54.5 ±
15.5 g m)2.7 vs. 45 ± 11.3 g m)2.7; P ¼ 0.0001)
in obese hypertensives with MS. These differences
were significant also after adjustment for age, sex,
24-h blood pressures and duration of hypertension
(P ¼ 0.02 and 0.007 respectively).
As shown in Table 2, mid-wall fractional shor-
tening and the mitral E-wave/A-wave ratio were
lower and E-wave deceleration time was longer in
hypertensive patients with MS when compared with
those without it. These results, with the exception of
the E-wave/A-wave ratio, held also after adjustment
for age, gender, 24-h systolic and diastolic BP, and
duration of hypertension.
When we looked at renal and retinal indices of
hypertensive target organ damage (presented in
Table 3), we found that the AER and prevalence of
microalbuminuria (Fig. 1b) were significantly high-
er in hypertensive subjects with MS, even after
adjusting for age, gender, 24-h systolic and diastolic
BP, and duration of hypertension. The chance of
having microalbuminuria remained greater in the
group of patients with MS also taking into account
age, gender, 24-h systolic and diastolic BP, duration
of hypertension, and previous antihypertensive
therapy (OR ¼ 2.45, 95% CI: 1.44–4.18; P ¼
0.0001). The difference regarding AER as a con-
tinuous variable, was also confirmed in the sub-
group of untreated patients with MS (n ¼ 37) when
compared with those without MS (n ¼ 86) (P ¼
0.0001), even after correction for age and 24-h
systolic BP (P ¼ 0.006).
Similar conclusions were also reached when
comparing obese subjects with MS (n ¼ 93) to those
without MS (n ¼ 43), AER being higher in the
former than in the latter [13.9 (6–26.5) vs. 9.9
(6.6–18) lg min)1; P ¼ 0.04, after correction for
age, sex, duration of hypertension and levels of BP].
The groups with and without MS did not differ
regarding serum creatinine and creatinine clearance
indexed for BSA, although, after controlling for age
and other confounding variables the latter param-
eter became significantly higher in hypertensive
patients with MS. The prevalence of hypertensive
retinopathy was greater in subjects with MS, even
after adjustment for age, gender, 24-h blood pres-
sures, duration of hypertension, and previous anti-
hypertensive therapy (OR ¼ 1.99, 95% CI: 1.13–
3.52; P ¼ 0.01).
Linear multiple regression analysis, aiming to
explore the independent determinants of LV mass,
revealed that in a model (R2 ¼ 0.33) including age,
Table 3 Renal and retinal parameters of the overall study population and of the two subgroups with and without metabolic syndrome (MS)
Overall study
population (n ¼ 353)
Patients with
MS (n ¼ 130)
Patients without
MS (n ¼ 223) P P adjusted*
Serum creatinine (lmol L)1) 72.5 ± 15.9 70.7 ± 18.6 73.4 ± 15 0.23 0.89
Creatinine clearance (mL min m)2) 111.4 ± 26.7 114.2 ± 27.4 109.8 ± 26.2 0.14 0.0006
Albumin excretion rate (lg min)1)a 10.7 (6.4–23.9) 14.3 (6.4–27.9) 9.7 (6.4–19.3) 0.006 0.007
Prevalence of hypertensive retinopathy 222 (62.9) 114 (87.7) 108 (48.4) <0.00001 0.004
Grade 1 KWB classification 136 (38.5) 63 (48.5) 73 (32.7) 0.005 –
Grade 2 KWB classification 84 (23.8) 50 (38.4) 34 (15.2) <0.00001 –
Grade 3 KWB classification 2 (0.6) 1 (0.8) 1 (0.5) – –
Grade 4 KWB classification 0 (0) 0 (0) 0 (0) – –
Values are presented as mean ± SD or n (%) unless indicated. KWB, Keith–Wagener–Barker.
aMedian (interquartile range).
*Adjustment was made for age, gender, 24-h systolic and diastolic BP and duration of hypertension.
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sex, duration of hypertension, previous antihyper-
tensive therapy, AER, glycaemia, HDL, triglycerides,
waist circumference, and 24-h systolic and diastolic
blood pressures, the following parameters remained
significant predictors of LVMH2.7: age (b ¼ 0.19;
P ¼ 0.0001), male gender (b ¼ 0.15; P ¼ 0.002),
duration of hypertension (b ¼ 0.10; P ¼ 0.04), AER
(log-transformed) (b ¼ 0.12; P ¼ 0.01), waist cir-
cumference (b ¼ 0.34; P < 0.00001), 24-h systolic
BP (b ¼ 0.20; P ¼ 0.00009). When we added MS to
this model as a dummy variable (0 ¼ no; 1 ¼ yes),
MS continued to be associated with LVMH2.7 (b ¼
0.20; P ¼ 0.00009), independently of its individual
components and other covariates. A similar associ-
ation between MS and LV mass (b ¼ 0.21; P ¼
0.0003) was obtained when the single components
of MS, with the exception of blood pressures, were
introduced into this multivariate model as dichot-
omous rather than continuous variables.
Analogous conclusions were also reached when
ridge multiple regression analysis was used to
overcome the problem of multicollinearity. In par-
ticular, for a lambda of 0.09, the ridge standardized
coefficient of regression relating MS to LVMH2.7 was
0.19 (P ¼ 0.0001). The inclusion in the multivari-
ate model of clinic systolic and diastolic BP values,
instead of the corresponding 24-h ambulatory BP,
did not significantly modify the results. The same
was true when waist circumference was replaced by
the body mass index. Similar findings were also
obtained when adopting LVMI as dependent vari-
able, instead of LVMH2.7.
When a multiple regression model was built to
assess the independent correlates of AER, glycaemia
(b ¼ 0.14; P ¼ 0.007) and 24-h systolic BP (b ¼
0.16; P ¼ 0.002) emerged as the main predictors
of AER. When this model was run again after
adding MS, along with its individual components
and other potential confounders, MS continued to
be related to the AER (b ¼ 0.12; P ¼ 0.03), even
when we calculated the standardized ridge coeffi-
cient of regression (b ¼ 0.11; P ¼ 0.03, for a
lambda of 0.46) to avoid the problems of multicol-
linearity.
Discussion
The main finding of the present study was the
identification of a close association between MS,
defined in accordance with NCEP-ATPIII criteria,
and some indices of preclinical cardiac, renal and
retinal damage. With regard to echocardiographic
parameters, hypertensive patients with MS exhibited
higher LV mass (either normalized by BSA or by
height elevated by a power of 2.7), relative wall
thickness, left atrial size, and greater prevalence of
LV hypertrophy, lower mid-wall fractional shorten-
ing and a longer E-wave deceleration time than
subjects without MS. These results were maintained
even after correction for several confounding vari-
ables, such as age, gender distribution, severity and
duration of hypertension and previous antihyper-
tensive therapy. In particular, after adjustment for
these covariates, the likelihood of LV hypertrophy
was 2.89-fold (95% CI: 1.68–4.98) higher in sub-
jects with MS than in those without it, when LV
mass was indexed by height2.7.
Moreover, it is noteworthy that the relationship
between MS and LV mass was confirmed in multi-
variate regression models including MS together
with its individual components, as independent
variables; this suggests that MS may have a
deleterious effect on cardiac structure over and
above the potential contribution of each single
component of this syndrome, and that the conflu-
ence of abnormalities that comprise MS may have a
synergistic negative impact on LV mass. The data in
the present study, obtained from a wide sample of
White hypertensive patients, concurs with the
results of two previous investigations conducted on
the general population [16] and hypertensive sub-
jects [17].
In the Strong Heart Study, a longitudinal
investigation conducted in American Indian com-
munities, a subset of the study population, inclu-
ding 1436 non-diabetic participants without
prevalent cardiovascular disease (61.2% of which
had high BP), was examined to analyse the impact
of the MS on cardiac structure and function.
Subjects with MS showed greater LV dimension,
mass and relative wall thickness, and left atrial
diameter, and a higher prevalence of LV hypertro-
phy, with lower mid-wall shortening than those
who did not have MS [16]. Cuspidi et al. [17], in
447 untreated middle-aged hypertensives, found
that patients with MS had a more pronounced
cardiac and extra-cardiac involvement than those
without it.
Our paper, being a clinical study with a cross-
sectional design, only permits us to make hypotheses
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about the association of MS with cardiac hyper-
trophy. For example, the latter might be explained
by insulin resistance and the accompanying com-
pensatory hyperinsulinaemia, which are regarded
as the patho-physiological key features underlying
the MS [1]. Trophic effects of insulin on myocardial
tissue have been demonstrated in cell cultures and
animal models [18, 19] and could be mediated, at
least in part, by the insulin-like growth factor-1
receptors [20, 21]. However, the in vivo studies
that have sought an association between insulin
and LV mass have yielded conflicting results
[21–27].
Moreover, insulin may affect LV mass indirectly
by increasing sodium retention [28, 29] or endo-
thelin-1 levels [30, 31] or by inducing sympathetic
activation [32–34]. Other potential biological medi-
ators of LV hypertrophy in subjects with MS may be
certain peptide hormones, secreted from white
adipose tissue, such as angiotensin II, a potent
growth factor in myocardial tissue [35], and leptin,
whose mitogenic effect in cardiomyocytes has been
recently evaluated with discrepant conclusions [27,
36–38].
There are other important findings from our study
that deserve a special mention: the greater level of
AER and the consequent higher prevalence of
microalbuminuria, and the more elevated age-
adjusted creatinine clearance values, observed in
hypertensive subjects with MS in comparison with
those without it. These results are in keeping with a
recent cross-sectional evaluation of the Third
National Health and Nutrition Examination Survey
data in 5360 US civilian non-institutionalized sub-
jects, in which a close association was found
between microalbuminuria and MS (defined accord-
ing to NCEP-ATPIII criteria) [39]. In the same study,
as well as in ours, the main predictors of microal-
buminuria were blood pressure and glucose levels
[39].
The relationship between AER and MS is so close
that WHO recommendations include microalbu-
minuria amongst the criteria for diagnosing MS
[1]. Indeed, the inclusion of microalbuminuria as
part of the MS has been controversial because its
association with insulin resistance has been des-
cribed in several [40–42], but not all, reports [43,
44]. Glomerular hyperfiltration, expressed by an
increased creatinine clearance rate, is a functional
renal change that precedes glomerulosclerosis
[45–47]; it is associated with obesity [48] and with
insulin resistance [49].
Several studies showed that the MS confers an
increased risk of cardiovascular morbidity and
mortality [4–6, 50]. Recently it has been demon-
strated that the adverse prognostic impact of MS
may also be extended to hypertensive patients [7].
Indeed, in the Progetto Ipertensione Umbria Moni-
toraggio Ambulatoriale study, a prospective obser-
vational investigation of Italian adult subjects with
essential hypertension, those patients with this
syndrome (34% of the whole population), defined
in accordance with NCEP-ATPIII criteria, ran an
increased risk of developing cardiac and cerebrovas-
cular events. The risk was attenuated but still
significant amongst participants without diabetes
mellitus [7].
It is likely that the enhanced cardiovascular risk
associated with MS may be partly mediated through
an increased prevalence of preclinical cardiovascular
and renal changes in patients with essential hyper-
tension and MS. Indeed, preclinical cardiac and
renal abnormalities, such as LV hypertrophy and
microalbuminuria, are recognized as significant
independent predictors of adverse cardiovascular
outcomes [11, 50–53].
Another finding from our study merits a com-
ment, this being the increased prevalence of grade I
and grade II hypertensive retinopathy observed in
subjects with MS when compared with persons
without MS. This result is consistent with a recent
cross-sectional investigation involving 11 265 par-
ticipants in the Atherosclerosis Risk in Communities
Study, in which associations were noted between
MS and arterio-venous nicking, focal arteriolar
narrowing and generalized arteriolar narrowing,
even in people without diabetes or hypertension
[54]. However the prognostic significance of this
finding is unclear, because the studies exploring the
association between the first two degrees of hyper-
tensive retinopathy and cardiovascular outcomes
have shown inconsistent results [55]. Some other
aspects of our paper need to be discussed.
First, the greater proportion of women observed in
the group with MS. It was explained by a greater
prevalence of visceral obesity and of low HDL values
in females than in males. The over-representation of
women in the MS group may appear surprising in
the light of the higher percentage of males reported
in MS in previous papers, such as in the Botnia study
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[50], in which the WHO criteria [1] were used to
diagnose MS. These criteria require very different
limits and modalities to define obesity and low HDL
values, from those proposed by the NCEP-ATPIII
definition of MS. Indeed, when the latter definition
was used it was frequently observed that there was
no gender difference [7, 17] or there was a greater
proportion of women in the MS group [16, 39, 56,
57], as was the case in our study.
Secondly, previous antihypertensive treatment
that had been stopped may have affected the results
because of the persisting influence on target organ
damage, even though patients’ blood pressure may
have returned to control values. However, in the
subset of hypertensive patients who had never
pharmacologically treated we found results similar
to those obtained in the whole population, with
regard to LV mass and the AER. Moreover, the
greater extent of preclinical cardiac, renal and
retinal damage in patients with MS was confirmed,
also taking into account previous treatment in
multivariate analyses.
Thirdly, patients with MS were older and showed
more elevated systolic BP and a longer duration of
hypertension, than those without MS. These factors
may partially explain the greater extent of end-organ
damage found in subjects with MS. However, the
differences regarding LVM, prevalence of LV hyper-
trophy, AER and prevalence of microalbuminuria
remained significant after adjustment for these cova-
riates, even in the subgroups of untreated patients.
In conclusion, MS seems to amplify hypertension-
related cardiac and renal changes, over and above
the potential contribution of each single component
of this syndrome. As these markers of target organ
damage are well-known predictors of cardiovascular
events, our results may partly explain the enhanced
cardiovascular risk associated with MS.
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